• Alaunos Therapeutics believes it has regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement.
• A $350 million financing closed October 14, 2026, bolstering equity alongside a cash settlement waiver covering approximately $9 million of preferred stock.
• Nasdaq confirmation remains pending; a delisting hearing scheduled for November 10, 2026, is expected to be canceled upon confirmation.
• Continued listing remains at risk if the fiscal 2026 annual report fails to demonstrate compliance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alaunos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-427890), on October 21, 2026, and is solely responsible for the information contained therein.